169 related articles for article (PubMed ID: 20137931)
1. Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode.
Meyers MJ; Pelc M; Kamtekar S; Day J; Poda GI; Hall MK; Michener ML; Reitz BA; Mathis KJ; Pierce BS; Parikh MD; Mischke DA; Long SA; Parlow JJ; Anderson DR; Thorarensen A
Bioorg Med Chem Lett; 2010 Mar; 20(5):1543-7. PubMed ID: 20137931
[TBL] [Abstract][Full Text] [Related]
2. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
Zhou T; Commodore L; Huang WS; Wang Y; Sawyer TK; Shakespeare WC; Clackson T; Zhu X; Dalgarno DC
Chem Biol Drug Des; 2010 Jan; 75(1):18-28. PubMed ID: 19895503
[TBL] [Abstract][Full Text] [Related]
3. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.
Simard JR; Getlik M; Grütter C; Schneider R; Wulfert S; Rauh D
J Am Chem Soc; 2010 Mar; 132(12):4152-60. PubMed ID: 20201574
[TBL] [Abstract][Full Text] [Related]
4. 3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor.
Scott DA; Dakin LA; Del Valle DJ; Diebold RB; Drew L; Gero TW; Ogoe CA; Omer CA; Repik G; Thakur K; Ye Q; Zheng X
Bioorg Med Chem Lett; 2011 Mar; 21(5):1382-4. PubMed ID: 21295474
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2.
Nie Z; Perretta C; Erickson P; Margosiak S; Almassy R; Lu J; Averill A; Yager KM; Chu S
Bioorg Med Chem Lett; 2007 Aug; 17(15):4191-5. PubMed ID: 17540560
[TBL] [Abstract][Full Text] [Related]
6. Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase.
Scott DA; Balliet CL; Cook DJ; Davies AM; Gero TW; Omer CA; Poondru S; Theoclitou ME; Tyurin B; Zinda MJ
Bioorg Med Chem Lett; 2009 Feb; 19(3):697-700. PubMed ID: 19112018
[TBL] [Abstract][Full Text] [Related]
7. Displacement assay for the detection of stabilizers of inactive kinase conformations.
Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping.
Richardson CM; Nunns CL; Williamson DS; Parratt MJ; Dokurno P; Howes R; Borgognoni J; Drysdale MJ; Finch H; Hubbard RE; Jackson PS; Kierstan P; Lentzen G; Moore JD; Murray JB; Simmonite H; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2007 Jul; 17(14):3880-5. PubMed ID: 17570665
[TBL] [Abstract][Full Text] [Related]
10. Design of potent IGF1-R inhibitors related to bis-azaindoles.
Nemecek C; Metz WA; Wentzler S; Ding FX; Venot C; Souaille C; Dagallier A; Maignan S; Guilloteau JP; Bernard F; Henry A; Grapinet S; Lesuisse D
Chem Biol Drug Des; 2010 Aug; 76(2):100-6. PubMed ID: 20545947
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
[TBL] [Abstract][Full Text] [Related]
12. Discovery of pyrrolopyrimidine inhibitors of Akt.
Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
[TBL] [Abstract][Full Text] [Related]
13. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
[TBL] [Abstract][Full Text] [Related]
15. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
16. Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way.
Uitdehaag JC; Sünnen CM; van Doornmalen AM; de Rouw N; Oubrie A; Azevedo R; Ziebell M; Nickbarg E; Karstens WJ; Ruygrok S
J Biomol Screen; 2011 Oct; 16(9):1007-17. PubMed ID: 21873591
[TBL] [Abstract][Full Text] [Related]
17. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR.
Takayama T; Umemiya H; Amada H; Yabuuchi T; Shiozawa F; Katakai H; Takaoka A; Yamaguchi A; Endo M; Sato M
Bioorg Med Chem Lett; 2010 Jan; 20(1):108-11. PubMed ID: 19945869
[TBL] [Abstract][Full Text] [Related]
18. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
[TBL] [Abstract][Full Text] [Related]
19. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP
ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors.
Peng YH; Shiao HY; Tu CH; Liu PM; Hsu JT; Amancha PK; Wu JS; Coumar MS; Chen CH; Wang SY; Lin WH; Sun HY; Chao YS; Lyu PC; Hsieh HP; Wu SY
J Med Chem; 2013 May; 56(10):3889-903. PubMed ID: 23611691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
